97 phenotypes from 5 alleles in 20 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Mmp9tm1Amr/Mmp9+ B6.Cg-Mmp9tm1Amr	decreased myocardial infarct size	J:102541
Mmp9tm1Amr/Mmp9tm1Amr B6.Cg-Mmp9tm1Amr	decreased myocardial infarct size	J:102541
Mmp9tm1Arnd/Mmp9tm1Arnd B6.129P2-Mmp9tm1Arnd	decreased histamine level	J:110450
	increased prostaglandin level	J:110450
	increased vascular permeability	J:110450
Mmp9tm1Arnd/Mmp9tm1Arnd involves: 129P2/OlaHsd	decreased litter size	J:64545
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:58833
	reduced fertility	J:64545
Mmp9tm1b(EUCOMM)Wtsi/Mmp9tm1b(EUCOMM)Wtsi C57BL/6N-Mmp9tm1b(EUCOMM)Wtsi/Ics	short tibia	J:211773
Mmp9tm1Itoh/Mmp9tm1Itoh involves: 129P2/OlaHsd * C57BL/6J	decreased metastatic potential	J:55823
Mmp9tm1Tvu/Mmp9tm1Tvu 129S6/SvEvTac-Mmp9tm1Tvu	normal immune system phenotype	J:113463
Mmp9tm1Tvu/Mmp9tm1Tvu B6.129S6-Mmp9tm1Tvu	abnormal tumor morphology	J:105098
	decreased tumor incidence	J:105098
Mmp9tm1Tvu/Mmp9tm1Tvu C3N.129S6-Mmp9tm1Tvu	decreased susceptibility to bacterial infection	J:150311
	decreased susceptibility to induced arthritis	J:150311
	joint inflammation	J:150311
	joint swelling	J:150311
Mmp9tm1Tvu/Mmp9tm1Tvu either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * CD-1)	abnormal long bone epiphyseal plate morphology	J:47297
	abnormal long bone hypertrophic chondrocyte zone	J:47297
	abnormal metatarsal bone morphology	J:47297
	abnormal trabecular bone morphology	J:47297
	decreased length of long bones	J:47297
	delayed bone ossification	J:47297
	increased width of hypertrophic chondrocyte zone	J:47297
	osteopetrosis	J:47297
	short femur	J:47297
	short tibia	J:47297
Mmp9tm1Tvu/Mmp9tm1Tvu either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6J)	abnormal angiogenesis	J:95880
Mmp9tm1Tvu/Mmp9tm1Tvu either: FVB.129S6-Mmp9tm1Tvu or (involves: 129S6/SvEvTac)	abnormal response to cardiac infarction	J:68211
Mmp9tm1Tvu/Mmp9tm1Tvu FVB.129S6-Mmp9tm1Tvu	abnormal neutrophil physiology	J:104644
	abnormal physiological neovascularization	J:104786
	abnormal response to cardiac infarction	J:104786
	decreased susceptibility to induced colitis	J:104644
	decreased susceptibility to xenobiotic induced morbidity/mortality	J:104644
	normal immune system phenotype	J:104644
	increased angiogenesis	J:104786
	increased ventricle muscle contractility	J:104786
Mmp9tm1Tvu/Mmp9tm1Tvu FVB.Cg-Mmp9tm1Tvu/J	abnormal intestinal goblet cell morphology	J:128322
	abnormal response/metabolism to endogenous compounds	J:147593
	decreased susceptibility to Flaviviridae infection	J:153406
	decreased susceptibility to Flaviviridae infection induced morbidity/mortality	J:153406
	decreased susceptibility to injury	J:133660, J:148923
	enhanced blood-brain barrier function	J:153406
	hypoalgesia	J:133660
	increased body weight	J:147593
	increased tibialis anterior weight	J:147593
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129/Sv * 129S6/SvEvTac	decreased circulating interleukin-10 level	J:55723
	increased susceptibility to type IV hypersensitivity reaction	J:55723
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac	abnormal chemokine level	J:84293
	abnormal dendritic cell physiology	J:84293
	abnormal impulse conducting system conduction	J:148442
	abnormal induced retina neovascularization	J:113620
	abnormal Langerhans cell physiology	J:76157
	abnormal myelination	J:105765
	abnormal myocardial fiber physiology	J:148442
	abnormal vascular smooth muscle physiology	J:109006
	abnormal vascular wound healing	J:109006
	cardiac fibrosis	J:148442
	decreased cardiac muscle contractility	J:148442
	decreased dendritic cell number	J:84293
	decreased IgE level	J:84293
	decreased inflammatory response	J:84293
	decreased oligodendrocyte number	J:105765
	decreased physiological sensitivity to xenobiotic	J:84293
	decreased susceptibility to induced aneurysm formation	J:62760
	decreased susceptibility to injury	J:79422, J:91478, J:114188
	increased circulating interferon-beta level	J:148442
	increased circulating interferon-gamma level	J:148442
	increased heart left ventricle posterior wall thickness	J:148442
	increased susceptibility to dystrophic cardiac calcinosis	J:148442
	increased susceptibility to Picornaviridae infection	J:148442
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:148442
	myocarditis	J:148442
	thick interventricular septum	J:148442
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * C57BL/6	abnormal chemokine level	J:88065
	abnormal cytokine secretion	J:88065
	abnormal leukocyte morphology	J:88065
	abnormal response to infection	J:126519
	decreased interferon-gamma secretion	J:88065
	increased eosinophil cell number	J:88065
	increased IgE level	J:88065
	increased interferon-gamma secretion	J:88065
	increased interleukin-4 secretion	J:88065
	increased interleukin-5 secretion	J:88065
	increased interleukin-13 secretion	J:88065
	increased lymphocyte cell number	J:88065
	increased macrophage cell number	J:88065
	increased monocyte cell number	J:88065
	increased T cell proliferation	J:88065
	increased T-helper 2 cell number	J:88065
	lung inflammation	J:88065
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac	impaired contextual conditioning behavior	J:105763
	reduced long-term potentiation	J:105763
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * C57BL/6J	abnormal angiogenesis	J:101783
	abnormal vascular smooth muscle physiology	J:101783
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * CD-1	abnormal bone marrow cell physiology	J:149957
	abnormal hematopoietic stem cell morphology	J:149957
	abnormal megakaryocyte differentiation	J:149957
	abnormal retina apoptosis	J:129161
	decreased susceptibility to injury	J:129161
	decreased susceptibility to ischemic brain injury	J:79535
	impaired hematopoiesis	J:149957
	impaired myelopoiesis	J:149957
	increased susceptibility to xenobiotic induced morbidity/mortality	J:149957
Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * FVB/N	decreased neuron apoptosis	J:96548
	delayed wound healing	J:150790